Ana María Moreno Fernández

📢 𝗔𝗘𝗠𝗣𝗦 𝘄𝗶𝗹𝗹 𝘀𝘁𝗮𝗿𝘁 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗣𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝗥𝗲𝗽𝗼𝗿𝘁𝘀 (𝗧𝗣𝗥𝘀) 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝘄𝗶𝘁𝗵 𝗮 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗖𝗛𝗠𝗣 𝗼𝗽𝗶𝗻𝗶𝗼𝗻 𝗮𝘁 𝘁𝗵𝗲 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟰 𝗺𝗲𝗲𝘁𝗶𝗻𝗴. 𝗡𝗲𝘄 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀:  - 𝗔𝘄𝗶𝗾𝗹𝗶 (insulin icodec): from Novo Nordisk A/S, indicated for the treatment of diabetes mellitus in adults. - 𝗘𝗺𝗯𝗹𝗮𝘃𝗲𝗼 (aztreonam / avibactam): from Pfizer Europe Ma EEIG, indicated for the treatment of the following infections in adult patients: o Complicated intra-abdominal infection (IIAc). o Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP). o Complicated urinary tract infection (cUTI), including pyelonephritis. Emblaveo is also indicated for the treatment of infections caused by aerobic gram-negative microorganisms in adult patients with limited therapeutic options. - 𝗙𝗮𝗯𝗵𝗮𝗹𝘁𝗮 (iptacopan): from Novartis Europharm Limited, indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) presenting with haemolytic anaemia. - 𝗟𝘆𝘁𝗲𝗻𝗮𝘃𝗮 (bevacizumab gamma): from Outlook Therapeutics Limited, indicated for the treatment of neovascular (wet) age-related macular degeneration in adult patients. And also, 𝗻𝗲𝘄 𝗶𝗻𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗕𝗶𝗺𝘇𝗲𝗹𝘅 (bimekizumab), 𝗡𝗶𝗹𝗲𝗺𝗱𝗼 (bempedoic acid), 𝗡𝘂𝘀𝘁𝗲𝗻𝗱𝗶 (bempedoic acid/ezetimibe), 𝗢𝗻𝗶𝘃𝘆𝗱𝗲 𝗽𝗲𝗴𝘆𝗹𝗮𝘁𝗲𝗱 𝗹𝗶𝗽𝗼𝘀𝗼𝗺𝗮𝗹 (irinotecan free anhydrous base), 𝗥𝗲𝘁𝘀𝗲𝘃𝗺𝗼 (selpercatinib) and 𝗫𝘁𝗮𝗻𝗱𝗶 (enzalutamide). Link: https://lnkd.in/d-77a3fx #Pharmaceuticals #TPR #AEMPS #MarketAccess #Spain

14

🔎📣#InsPHotlight Pulmonary Hypertension (PH) specialists from across the globe convened in Barcelona for Ferrer's 6th annual #IMPAHCT meeting, with a strong emphasis on patient advocacy. 𝗡𝗼𝘁𝗮𝗯𝗹𝘆, 𝗛𝗮𝗹𝗹 𝗦𝗸𝗮𝗮𝗿𝗮, 𝗿𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗶𝗻𝗴 𝗣𝗛𝗔 𝗘𝘂𝗿𝗼𝗽𝗲, 𝘄𝗮𝘀 𝘁𝗵𝗲 𝘀𝗼𝗹𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗮𝗱𝘃𝗼𝗰𝗮𝘁𝗲 𝗽𝗿𝗲𝘀𝗲𝗻𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘀𝗲𝗰𝗼𝗻𝗱 𝘁𝗶𝗺𝗲 𝗮𝘁 𝘁𝗵𝗲 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲. The agenda featured discussions on diagnosing and classifying PH, with experts highlighting the challenges of the current system, especially for patients with multiple comorbidities. Biomarkers like NT-ProBMP were also explored for their potential to improve patient outcomes. Later, the focus shifted to the patient experience. PH-ILD patients (Group 3) shared their struggles through a Ferrer-initiated study. Hall Skaara then emphasized the importance of patient involvement in treatment decisions and pharmaceutical trials. He highlighted the value of Patient Reported Outcome Measures (PROMs) like emPHasis-10, which can improve communication between patients and doctors. "Coffee with the expert" sessions allowed attendees to gain insights from leading PH specialists. Talks by Professor Olivier Sitbon and Professor Michele D'Alto offered groundbreaking information on managing high-risk patients and the importance of right heart ventricle assessment. The conference also explored how PH management varies globally, with representatives from Colombia, Mexico, Taiwan, and Spain sharing their experiences. A key takeaway was the impact of factors like medication access, altitude, and patient demographics on treatment approaches. The final session addressed the unique challenges of managing PH-ILD, a complex condition with limited treatment options. The conference concluded with a poster presentation ceremony, where Hall Skaara presented his own work on the patient experience of living with PH. PHA Europe commends Ferrer's commitment to patient-centric care and their role in amplifying patient voices at key industry conferences.👏🙌 ➡️Read more about PHA Europe's initiative: www.phaeurope.org #pulmonaryhypertension #awareness #patientempowerment #PHAEurope #WeBreatheUnited #PAH #WPHD #PHAEurope #patients #accesstocare #ILD Ferrer Hipertensión Pulmonar Argentina PH Belgium - Pulmonale Hypertensie vzw Hipertensión Pulmonar España ORG Pacientes Fundación Contra la Hipertensión Pulmonar Asociación Nacional de Hipertensión Pulmonar ANHP Stichting Pulmonale Hypertensie / PH Association the Netherlands PH Serbia AIPI Italian Pulmonary Hypertension Association Fundación Ayúdanos a Respirar

21

New Data Show Almirall´s EBGLYSS® (Lebrikizumab) Provided Sustained Disease Control for up to Three Years in More Than 80% of Adults and Adolescents With Moderate-to-severe Atopic Dermatitis Monthly lebrikizumab maintenance dosing sustained clear or almost-clear skinfor up to three years in the vast majority (more than 80%) of ADvocate 1 and 2 responders Nearly 87 percent of patients taking lebrikizumab did not require either high-potency topical corticosteroids or systemic treatments during the three-year period The safety profile at three years was consistent with the previously published two-year results BARCELONA, Spain I September 25, 2024 I More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing. Almirall S.A. (BME: ALM) announced these new long-term results from the ADjoin long-term extension study, which will be presented as a late breaker at the European Academy of Dermatology and Venereology (EADV) Congress from Sept. 25-28 in Amsterdam, Netherlands.1 Lebrikizumab is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity.2,3,4, The cytokine IL-13 is key in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection.5,6 “Moderate-to-severe atopic dermatitis imposes a significant burden on patients, affecting their quality of life and overall wellbeing,” said Prof. Dr. med. Diamant Thaçi, Director at the Institute and Comprehensive Centre for Inflammation Medicine, in Lübeck, Germany. “These new three-year clinical data demonstrate the potential this biologic treatment has to provide sustained relief from this disease, offering long-term benefits to people living with this chronic and relapsing condition.” Patients taking lebrikizumab who completed 52 weeks in ADvocate 1 or 2 could enroll in ADjoin for an additional 100 weeks of continued treatment (up to 152 weeks of continuous treatment). Patients in this analysis of the long-term extension trial received treatment either 250 mg every two weeks (Q2W) or once monthly (Q4W). The approved maintenance dose of lebrikizumab is 250 mg Q4W. These data presented are part of ADjoin, the long-term extension study of the lebrikizumab trials, and include participants who responded to lebrikizumab treatment at Week 16 from ADvocate 1 and ADvocate 2.1 Source- https://lnkd.in/gzJwFbae #news #pipeline #business #trend #trend

1

Discover how the 5th ICSM in 📍 Madrid, Spain 📍 will redefine the future of sexual medicine! Purpose⬇️ The main objectives of the ICSM are to help transform evolving new data into knowledge, knowledge into recommendations and recommendations into improved patient care. The final document will be the result of evidence-based medicine, complimented by vast clinical experience and our enhanced understanding of disease processes, which can impact sexual health. Mission Statement⬇️ To develop an authoritative comprehensive all-encompassing consensus document highlighting state of the art knowledge and management for male and female sexual health issues; based on the peer-reviewed medical literature and expertise of experts worldwide. To learn more, visit 🔗 icsm2024.org for more info + to register! #sexualmedicine #sexualhealth #MadridSpain #pelvichealth #pelvicpain #sexmed

3

🌟 Reminder: Dr. Josep Tabernero MD, PhD Tabernero's Insights at ESMO 2024 🌟 As we reflect on the highlights from #ESMO2024, this is a reminder of the impactful presentations and discussions led by Dr. Josep Tabernero MD, PhD , a prominent figure in oncology research. Dr. Tabernero played a key role at the conference, including: Chairing an Industry Satellite Symposium on precision oncology for BRAF-mutant cancers, held on September 16, 2024. The session explored the latest strategies for managing BRAFV600 mutations in solid tumors, including melanoma, colorectal cancer, and non-small cell lung cancer, with an expert panel sharing insights on targeting these mutations for optimal patient outcomes. Presenting data from the BREAKWATER study, which evaluated the combination of encorafenib and cetuximab with chemotherapy in BRAF V600E-mutant metastatic colorectal cancer. The study showcased promising improvements in efficacy and safety, advancing the potential treatment options for this challenging cancer type. Dr. Josep Tabernero MD, PhD’s contributions at ESMO continue to drive progress in targeted cancer therapies and precision medicine, providing hope for patients with hard-to-treat cancers. For more details, check out the full presentation and updates: https://lnkd.in/e2xXwUiq Stay tuned for more updates and reflections on #ESMO2024. #Oncology #CancerResearch #PrecisionOncology #TargetedTherapies #ColorectalCancer #BRAFMutations #JosepTabernero #BREAKWATERStudy

123

1 comentario

https://lnkd.in/gkMpDJEG     Article title: Direct action antivirals are effective in the total eradication of HCV in renal transplants   Author(s): Teresa Olea*, Inmaculada Castillo, Carlos Jiménez, Javier Bartolomé, María José Santana, JA Quiroga, Vicente Carreño and Rafael Selgas   Journal: Annals of Antivirals and Antiretrovirals   Journal ISSN: 2692-4625   Abstract: Introduction: The main objective of our study was to analyze the effectiveness of antiviral treatment (conventional or with direct-acting antivirals (DAA)) for total eradication of Hepatitis C Virus (HCV) in kidney transplant (KT) recipients. DAA are known drugs that are approved by FDA for clinical and pre-clinical investigations. The efficacy was analyzed by testing for the presence of HCV- ribonucleic acid (RNA) in the pellets obtained after ultracentrifugation of follow-up plasma samples and in peripheral blood mononuclear cells (PBMC) from patients with HCV infection who had achieved a sustained virological response (SVR). The safety, and the renal and hepatic repercussions of the antiviral treatment were also evaluated.   Patients and methods: We evaluated 18 adults receiving KT, whose HCV infection had been treated with antiviral therapy. HCV RNA was tested by real-time RT-PCR in PBMC and in 2 ml of plasma after ultracentrifugation.   Results: The predominant HCV genotype was 1b (78.6%), followed by 3a (14.3%) and 2a-2c in 1 patient (7.1%). Of the 18 patients, 13 received treatment post-KT with DAA (8 as first treatment and 5 as retreatment due to relapse). The other 5 patients were responders to INF, INF-RBV and one to DAA pre-KT.   In none of the 14 recipients of KT treated with DAA the presence of HCV RNA was detected neither in PBMC nor in plasma after ultracentrifugation. Viral RNA was also undetectable in the PBMC of the 4 patients with SVR after treatment with IFN (monotherapy or with RBV). However, one of them was positive to HCV RNA in the ultracentrifuged plasma. This patient, male, and diagnosed with HCV genotype 1b, had received INF-PEG monotherapy prior #KidneyTransplantation #OccultHepatitisC #Antivirals   #HIV #AIDS #ViralImmunity #ViralVaccine #Bacteriophages #H1N1 #SwineFlu #Hepatitis #Interferons #IFNs #AntiretroviralTherapy #ViralVectors #CrossInfectionControl #CombinationTherapy #Peertechz #PeertechzPublications #ClinicalVirology #Retrovirology #EmergingViralDiseases #ProteaseInhibitors #ViralImmunology #ViralProteomics #ViralGenetics #ViralTherapy #HepatitisDiseases #HIVVirus #Retrovirus #AidsResearch #AntigenicVaccine #RNAInterferenceTechnology #ClinicalVirology #Viruses #HostDefenses #HostVirusInteraction #ViralVectorsGeneTherapy #ViralDiseases #ViralInfection #ViralTreatment #AntiViralResearch #AntiViralDrugs

2

Members of the REVERSE consortium from #Galicia, Spain are in action at the #SEIMC2024 congress today and tomorrow! The team are presenting their ePoster entitled “Preparation to the implementation - empiric antibiotic therapy guidelines for febrile neutropenia”, which looks at screening for resistant organisms and adjusting febrile neutropenia prophylaxis in patients with hematologic malignancies and BMTs. View the poster and explore the programme https://seimc2024.org/ Instituto de Investigación Sanitaria Galicia Sur Alejandro Araújo Ameijeiras European Commission FISEVI

4

A new CGRP treatment arrives to Spain. The innovative Migraine treatment by Abbvie has shown efficiency in episodic as well as chronic patients, with a reduction in the frequency and intensity of the crisis. As Elena Ruiz De la Torre says, "The lack of access to preventive treatment aggravates the situation, as only about 36.6% of patients who meet the criteria for this type of treatment are currently receiving it" However, this option can help improve the quality of life of many migraine sufferers. Read the whole article here: 🖇 https://bit.ly/3QMO5Ga

14

🌍💪 European Week Against Cancer 💪🌍. In this European Week Against Cancer, we want to highlight the importance of early detection, efficient treatment and comprehensive support for patients. It is a crucial moment to reflect on the advances and challenges we still face in the fight against this disease. At All.Can Spain, we work tirelessly to identify and alleviate inefficiencies in cancer care. We believe that an efficient, patient-centred healthcare system not only improves clinical outcomes, but also transforms the patient and family experience. Why is our work at All.Can Spain vital? 🌟 Resource Optimisation: We evaluate and propose improvements in resource management to maximise impact. Patient Empowerment: We promote a patient-centred approach, where their needs and voices are heard and valued. Research and Data: We use data and evidence to identify areas for improvement and measure progress. 🤝 We continue to work to ensure that every cancer patient receives the care they deserve, reducing inequalities and improving their quality of life. #EuropeanWeekAgainstCancer #AllCanSpain #FightAgainstCancer 

26

"Should rare cancers still be (in) a niche of oncology?" Andrés Cervantes, president of ESMO - European Society for Medical Oncology, reflects on how to address the unmet needs of the more than 5 million European patients suffering from #RareCancers. "Taken together, rare cancers – those with an annual incidence of less than 6 in 100,000 – represent nearly a quarter of all new diagnoses. As the identification of a wide range of tumour molecular profiles keeps reducing the frequency of almost every cancer subtype even in the more common conventional disease categories, patient selection and recruitment for clinical trials of new targeted agents is becoming more and more complex. This is an unprecedented opportunity to bring rare cancers to the forefront of oncology research and treatment in the future." 📖 Read the full article in the ESMO Daily Reporter https://lnkd.in/dwbHwHin #IDEA4RC #HealthData #EHDS #EuropeanHealthDataSpace

9

Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain. Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.  Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/gaVnBaRP #Olverembatinib #HQP1351 #GZD824 #TKI #CML #buildingblocks

1

🔍 Discover the cost-effectiveness of pharmacogenetic screening in treating Major Depressive Disorder (MDD). This approach could save costs and improve patient outcomes in the Spanish National Health System. Read more to understand the potential benefits and future implications. 🌐💡 #SyenzaNews #Pharmacogenetics #MajorDepression #CostEffectiveness #HealthcareInnovation https://lnkd.in/dgcPfFJc

5

2 comentarios

🤝 Thank you MEP Susana Solís Pérez for conveying your support to address #RareDiseases, particularly #SickleCellDisease, on a European level. With over 52,000 people affected in the region, this marks a significant step towards equitable healthcare access for patients with sickle cell disease in Spain and across Europe. Your dedication brings us closer to realizing a European Union where: • Enhanced access to treatment and addressing health inequalities are prioritized • Investments are made in training and skill development • An EU-wide SCD Registry is promoted • Newborn screening is implemented across 27 EU member states • Strategic dialogue with relevant stakeholders is fostered Read our manifesto, "The Hidden Struggle: Confronting Sickle Cell Disease Health Inequalities" ▶️ https://bit.ly/49NPz9T

53

1 comentario

New article in Drugs in Context Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study Jesús Calleja-Escudero, Víctor Barrondo, Andres Rodriguez Alonso, Francisco Gómez-Veiga, Joan Bestard, Antonio Gomez Caamaño, Anne-Sophie Grandoulier, Maria Pérez-Sampietro, Venancio Chantada Abal, Raúl Poza de Celis, on behalf of ANAREN Study Group Study to determine the patterns of prescription and compliance as well as quality of life changes in patients prescribed luteinizing hormone-releasing hormone agonists. #drugsincontext #prostatecancer #LHRHagonists #oncology https://lnkd.in/dmkGpDhm

2

The hidden costs of centralizing cancer care in Comprehensive Cancer Centers (CCCs)? 🤔 Our JCO Global Oncology article: how well-intentioned policies could strain Spain’s healthcare system and widen disparities. https://lnkd.in/da5-HQtS #cancercare #Oncology #HealthEquity

13

1 comentario

Impact of intervention of community pharmacists on cardiovascular outcomes in Spain: A systematic review. https://ow.ly/hcXM50Qx3E7 #Pharmacy #CommunityPharmacy #CardiovasculaIinterventions #SystematicReview #Cochrane #PRISMA-S

1

1 comentario

Comprehensive assessment of the regulatory landscape of PD-1 and PD-L1 inhibitors Miguel Bronchud https://lnkd.in/eZgB9vpe #OncoDaily #Oncology #Cancer #Health #Medicine

16